Cover; Contents; Chapter 1. Chemotherapy of Schistosomiasis mansoni; I. Introduction; II. Laboratory Maintenance of Schistosoma mansoni; III. Drug Testing in Vitro; IV. Drug Testing in Vivo; V. Preclinical Trials; VI. Clinical Trials; VII. Antischistosomal Drugs in Clinical Use; VIII. Compounds with Antischistosomal Activity; References; Chapter 2. The Behavioral Toxicity of Monoamine Oxidase-Inhibiting Antidepressants; I. Introduction; II. Methods; III. Iproniazid-Related Adverse Behavioral Changes; IV. Phenelzine-Related Adverse Behavioral Changes

V. Tranylcypromine-Related Adverse Behavioral ChangesVI. Adverse Behavioral Changes Associated with Other Monoamine Oxidase-Inhibiting Antidepressants; VII. Comparison of Adverse Behavioral Effects during Monoamine Oxidase Inhibitor Treatment with Those during Treatment with Other Antidepressant Drugs; VIII. Behavioral Effects of Monoamine Oxidase-Inhibiting Drugs in Animals of Possible Relevance to Their Behavioral Toxicity in Man; IX. Biochemical Effects of Monoamine Oxidase-Inhibiting Drugs in Animals and Man of Possible Relevance to Their Behavioral Effects; X. Discussion and Conclusions

V. Excretion of Persorbed ParticlesVI. Breakdown of Persorbed Particles; VII. Discussion; VIII. Future Developments; IX. Conclusion; References; Chapter 6. Pharmacological Control of the Synthesis and Metabolism of Cyclic Nucleotides; I. Introduction; II. Adenylate Cyclase; III. Guanylate Cyclase; IV. Cyclic Nucleotide Phosphodiesterases; V. Transport of Cyclic AMP; VI. Inhibition of Action of Cyclic AMP; VII. Directions of Future Research in Pharmacological Control of Cyclic Nucleotides; VIII. Clinical Implications; IX. Concluding Remarks; References